Celltrion (068270) Q2 2025 earnings summary

Executive summary

• Achieved record-high quarterly operating profit since merger, driven by a shift to high-margin products and operational efficiencies.

• Completed merger with Celltrion Healthcare, integrating development, production, and sales for enhanced operational efficiency and global competitiveness.

• Biologics sales grew 14.1% year-over-year, with young products more than doubling and now comprising 53% of sales.

• Expanded product portfolio with new biosimilars and innovative drugs, including U.S. FDA approval for Remsima SC (Zymfentra).

• Strengthened global direct sales network, especially in the U.S. and Europe, and continued investments in R&D and production capacity.

Financial highlights

• 2Q25 sales reached KRW 961.5B, up 9.9% year-over-year and 14.2% sequentially.

• H1 2025 consolidated revenue: KRW 1,803.4 billion; operating income: KRW 391.9 billion; net income: KRW 171.6 billion.

• Operating profit surged 234.5% year-over-year to KRW 242.5B, with OP margin expanding to 25.2%.

• Gross profit margin improved to 56.6% in 2Q25 from 42.1% in 2Q24.

• R&D expenses: KRW 229.7 billion, 12.7% of sales.

Outlook and guidance

• Young portfolio expected to exceed 60% of full-year sales in 2025.

• Five new biosimilar launches planned by end of 2025, expanding addressable market from $55B to $103B.

• 2025 revenue target: KRW 5 trillion; 2026 target: KRW 7 trillion.

• Further COGS ratio improvement anticipated as new products expand and R&D amortization ends.

• Ongoing share buybacks and enhanced shareholder return policy, including cash and stock dividends.